On February 9, Sansure Bio released an announcement on the appointment of senior management personnel.

Abbott and Cardiovascular Systems, Inc. announced a definitive agreement for Abbott to acquire CSI, a medical device company with an innovative atherectomy system used in treating peripheral and coronary artery disease.

DiaSorin and Cytek Biosciences, Inc. announced that Luminex Corporation, a wholly owned subsidiary of DiaSorin, has signed an agreement with Cytek to sell substantially all of its assets related to the Flow Cytometry & Imaging business unit.

On February 6, Shenzhen Mindray Bio-Medical Electronics Co., Ltd. and China Resources Pharmaceutical Commercial Group Co., Ltd. held a signing ceremony in the headquarter of Mindray in Shenzhen.

Ibex Medical Analytics has received CE mark for its pathology diagnostics platform, Galen Prostate, under the European Union’s (EU) In Vitro Diagnostic Medical Devices Regulation (IVDR).

The US Food and Drug Administration on Wednesday granted Emergency Use Authorization for Anavasi Diagnostics' molecular point-of-care AscencioDx COVID-19 Test Kit.

Recently, Sysmex and Shanghai Pinnacles Medical Technology Co., Ltd. reached a strategic cooperation.

Element Biosciences and Bio-Rad on Wednesday announced a partnership to demonstrate the Bio-Rad SEQuoia RNA sequencing library preparation portfolio on the Element Aviti benchtop sequencer.

Roche announced on Thursday that it has expanded a previous collaboration with Janssen Biotech to create companion diagnostics for targeted therapies.

January-December 2022 results rose significantly, with net profit attributable to shareholders of the listed company amounting to CNY 1,720 million to 1,880 million, representing a year-on-year net profit growth of 101.84% to 120.62%.

Illumina, Inc. (Nasdaq: ILMN) today announced its financial results for the fourth quarter and fiscal year 2022, which include consolidated financial results for GRAIL.

Becton Dickinson announced on Wednesday that it has received Emergency Use Authorization from the US Food and Drug Administration for its combination COVID-19, influenza A/B, and respiratory syncytial virus test.

A-share listed Sinocare issued a full-year performance forecast. The Company expects a significant rise in January-December 2022 results, net profit attributable to shareholders of the listed company is CNY 400 million to 460 million, net profit increased by 271.85% to 327.63% year-on-year.

The US Food and Drug Administration in January modified existing 510(k) clearances for several firms, including Becton Dickinson and Roche, while it granted new clearances for diagnostic instruments and assays from Medica, Selux Diagnostics, and others, according to the agency website.

Qiagen reported on Tuesday that its fourth quarter sales declined 14 percent with an expected decrease in COVID-related sales offset by increased sales in the firm's non-COVID portfolio.